Endogenous antimicrobial peptides and skin infections in atopic dermatitis - PubMed (original) (raw)
Comparative Study
. 2002 Oct 10;347(15):1151-60.
doi: 10.1056/NEJMoa021481.
Affiliations
- PMID: 12374875
- DOI: 10.1056/NEJMoa021481
Free article
Comparative Study
Endogenous antimicrobial peptides and skin infections in atopic dermatitis
Peck Y Ong et al. N Engl J Med. 2002.
Free article
Abstract
Background: The innate immune system of human skin contains antimicrobial peptides known as cathelicidins (LL-37) and beta-defensins. In normal skin these peptides are negligible, but they accumulate in skin affected by inflammatory diseases such as psoriasis. We compared the levels of expression of LL-37 and human beta-defensin 2 (HBD-2) in inflamed skin from patients with atopic dermatitis and from those with psoriasis.
Methods: The expression of LL-37 and HBD-2 protein in skin-biopsy specimens from patients with psoriasis, patients with atopic dermatitis, and normal subjects was determined by immunohistochemical analysis. The amount of antimicrobial peptides in extracts of skin samples was also analyzed by immunodot blot analysis (for LL-37) and Western blot analysis (for HBD-2). Quantitative, real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays were used to confirm the relative expression of HBD-2 and LL-37 messenger RNA (mRNA) in the skin-biopsy specimens. These peptides were also tested for antimicrobial activity against Staphylococcus aureus with the use of a colony-forming assay.
Results: Immunohistochemical analysis confirmed the presence of abundant LL-37 and HBD-2 in the superficial epidermis of all patients with psoriasis. In comparison, immunostaining for these peptides was significantly decreased in acute and chronic lesions from patients with atopic dermatitis (P=0.006 and P=0.03, respectively). These results were confirmed by immunodot blot and Western blot analyses. Real-time RT-PCR showed significantly lower expression of HBD-2 mRNA and LL-37 mRNA in atopic lesions than in psoriatic lesions (P=0.009 and P=0.02, respectively). The combination of LL-37 and HBD-2 showed synergistic antimicrobial activity by effectively killing S. aureus.
Conclusions: A deficiency in the expression of antimicrobial peptides may account for the susceptibility of patients with atopic dermatitis to skin infection with S. aureus.
Copyright 2002 Massachusetts Medical Society
Comment in
- Antimicrobial peptides in health and disease.
Zasloff M. Zasloff M. N Engl J Med. 2002 Oct 10;347(15):1199-200. doi: 10.1056/NEJMe020106. N Engl J Med. 2002. PMID: 12374882 No abstract available. - Antimicrobial peptides in the skin.
Fellermann K, Wehkamp J, Stange EF. Fellermann K, et al. N Engl J Med. 2003 Jan 23;348(4):361-3; author reply 361-3. doi: 10.1056/NEJM200301233480418. N Engl J Med. 2003. PMID: 12540655 No abstract available.
Similar articles
- Expression of antimicrobial peptides such as LL-37 and hBD-2 in nonlesional skin of atopic individuals.
Goo J, Ji JH, Jeon H, Kim MJ, Jeon SY, Cho MY, Lee SH, Choi EH. Goo J, et al. Pediatr Dermatol. 2010 Jul-Aug;27(4):341-8. doi: 10.1111/j.1525-1470.2010.01122.x. Pediatr Dermatol. 2010. PMID: 20653851 - Expression and modulation of LL-37 in normal human keratinocytes, HaCaT cells, and inflammatory skin diseases.
Kim JE, Kim BJ, Jeong MS, Seo SJ, Kim MN, Hong CK, Ro BI. Kim JE, et al. J Korean Med Sci. 2005 Aug;20(4):649-54. doi: 10.3346/jkms.2005.20.4.649. J Korean Med Sci. 2005. PMID: 16100459 Free PMC article. - Changes of antimicrobial peptide mRNA expression in atopic eczema following phototherapy.
Gambichler T, Skrygan M, Tomi NS, Altmeyer P, Kreuter A. Gambichler T, et al. Br J Dermatol. 2006 Dec;155(6):1275-8. doi: 10.1111/j.1365-2133.2006.07481.x. Br J Dermatol. 2006. PMID: 17107401 - What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies.
Rupec RA, Boneberger S, Ruzicka T. Rupec RA, et al. Clin Dermatol. 2010 Jan-Feb;28(1):62-6. doi: 10.1016/j.clindermatol.2009.04.004. Clin Dermatol. 2010. PMID: 20082953 Review. - Expression of antimicrobial peptides in atopic dermatitis and possible immunoregulatory functions.
Kopfnagel V, Harder J, Werfel T. Kopfnagel V, et al. Curr Opin Allergy Clin Immunol. 2013 Oct;13(5):531-6. doi: 10.1097/ACI.0b013e328364ddfd. Curr Opin Allergy Clin Immunol. 2013. PMID: 23974683 Review.
Cited by
- New era of biologic therapeutics in atopic dermatitis.
Guttman-Yassky E, Dhingra N, Leung DY. Guttman-Yassky E, et al. Expert Opin Biol Ther. 2013 Apr;13(4):549-61. doi: 10.1517/14712598.2013.758708. Epub 2013 Jan 16. Expert Opin Biol Ther. 2013. PMID: 23323893 Free PMC article. Review. - Targeting IL-4 for the Treatment of Atopic Dermatitis.
Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Chiricozzi A, et al. Immunotargets Ther. 2020 Sep 29;9:151-156. doi: 10.2147/ITT.S260370. eCollection 2020. Immunotargets Ther. 2020. PMID: 33062619 Free PMC article. Review. - Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets.
Czarnowicki T, Esaki H, Gonzalez J, Malajian D, Shemer A, Noda S, Talasila S, Berry A, Gray J, Becker L, Estrada Y, Xu H, Zheng X, Suárez-Fariñas M, Krueger JG, Paller AS, Guttman-Yassky E. Czarnowicki T, et al. J Allergy Clin Immunol. 2015 Oct;136(4):941-951.e3. doi: 10.1016/j.jaci.2015.05.049. Epub 2015 Aug 1. J Allergy Clin Immunol. 2015. PMID: 26242300 Free PMC article. - Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.
Mercer DK, Torres MDT, Duay SS, Lovie E, Simpson L, von Köckritz-Blickwede M, de la Fuente-Nunez C, O'Neil DA, Angeles-Boza AM. Mercer DK, et al. Front Cell Infect Microbiol. 2020 Jul 7;10:326. doi: 10.3389/fcimb.2020.00326. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32733816 Free PMC article. Review. - Modulating immunity as a therapy for bacterial infections.
Hancock RE, Nijnik A, Philpott DJ. Hancock RE, et al. Nat Rev Microbiol. 2012 Mar 16;10(4):243-54. doi: 10.1038/nrmicro2745. Nat Rev Microbiol. 2012. PMID: 22421877 Review.
Publication types
MeSH terms
Substances
Grants and funding
- AI48176/AI/NIAID NIH HHS/United States
- AR41256/AR/NIAMS NIH HHS/United States
- HL36577/HL/NHLBI NIH HHS/United States
- HL37260/HL/NHLBI NIH HHS/United States
- HL46809/HL/NHLBI NIH HHS/United States
- M01 RR00051/RR/NCRR NIH HHS/United States
- T32 AI 07365/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical